Sunitinib Mechanism Of Action. Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors VEGFR1-3 platelet-derived growth factor receptors PDGFRα and PDGFRβ stem cell factor receptor c-kit glial cell-line derived neurotrophic factor receptorRET. 13 NONCLINICAL TOXICOLOGY Sections or subsections omitted from the full prescribing information are not. Gastrointestinal Stromal Tumor 142. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor approved multinationally for the first- and second-line treatment of metastatic renal cell carcinoma mRCC.
It is used to treat cancer. Renal Cell Carcinoma 143. Mechanism Of Action. Our studies indicate that sunitinib inhibits ccRCC growth primarily through an anti-angiogenic mechanism and not through direct targeting of ccRCC tumor cells. In vivo sunitinib downregulates myeloid-derived suppressor cells MDSC which are thought to contribute to the antitumor effects also. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor approved multinationally for the first- and second-line treatment of metastatic renal cell carcinoma mRCC.
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases RTKs some of which are implicated in tumor growth pathologic angiogenesis and metastatic progression of cancer.
Renal Cell Carcinoma 143. In phase I studies using intermittent dosing schedules oral administration of doses up to 50 mgday were reasonably well tolerated and resulted in plasma concentrations in the range of targeted levels needed for sustained kinase inhibition. 123 Pharmacokinetics 174 Concomitant Medications. Based on data from animal reproduction studies and its mechanism of action in utero exposure to sunitinib may cause fetal harm. It is a potent inhibitor of platelet - derived growth factor receptors PDGFRα and PDGFRβ vascular endothelial growth factor receptors VEGFR1. Multikinase inhibitor including VEGF and PDGF receptor tyrosine kinases some of which are implicated in tumor growth angiogenesis and metastasis.